Optimum treatment of congenital cytomegalovirus infection (Q38797872)

6 September 2017

Optimum treatment of congenital cytomegalovirus infection (English)

1 reference

6 September 2017

0 references

0 references

Marianne Leruez-Ville

series ordinal

1

1 reference

PubMed ID

27043943

6 September 2017

Yves Ville

series ordinal

2

1 reference

6 September 2017

4 April 2016

1 reference

Expert Review of Anti-infective Therapy

6 September 2017

1 reference

6 September 2017

14

1 reference

6 September 2017

5

1 reference

6 September 2017

479-488

1 reference

Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection

6 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based prediction model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Vaccine prevention of maternal cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Valganciclovir for symptomatic congenital cytomegalovirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Ganciclovir penetrates into the cerebrospinal fluid of an infant with congenital cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Detection of congenital cytomegalovirus infection by real-time polymerase chain reaction analysis of saliva or urine specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Brain magnetic resonance findings in symptomatic congenital cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Predictors of hearing loss in children with symptomatic congenital cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Is lenticulostriated vasculopathy a sign of central nervous system insult in infants with congenital CMV infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Lenticulostriated vasculopathy is a high-risk marker for hearing loss in congenital cytomegalovirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Effect on hearing of ganciclovir therapy for asymptomatic congenital cytomegalovirus infection: four to 10 year follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Ganciclovir treatment in children: evidence of subtherapeutic levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: implications for gene therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Genetic risks of antiviral nucleoside analogues--a survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Ganciclovir induces reproductive hazards in male rats after short-term exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Evidence based management guidelines for the detection and treatment of congenital CMV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Prediction of fetal infection in cases with cytomegalovirus immunoglobulin M in the first trimester of pregnancy: a retrospective cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Comparison of the LIAISON(®) CMV IgG Avidity II and the VIDAS(®) CMV IgG Avidity II assays for the diagnosis of primary infection in pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Modeling of human cytomegalovirus maternal-fetal transmission in a novel decidual organ culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy--a case-control study of the outcome in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Management of pregnancies with confirmed cytomegalovirus fetal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Cranial ultrasound scanning and prediction of outcome in newborns with congenital cytomegalovirus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

The prognostic value of ultrasound abnormalities and biological parameters in blood of fetuses infected with cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Cytomegalovirus-related fetal brain lesions: comparison between targeted ultrasound examination and magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Risk of cytomegalovirus-associated sequelae in relation to time of infection and findings on prenatal imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Identification of Symptomatic Fetuses Infected with Cytomegalovirus Using Amniotic Fluid Peptide Biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Testicular effects following in utero exposure to the antivirals acyclovir and ganciclovir in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Transfer of antivirals across the human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Placental transfer of ganciclovir in a woman with acquired immunodeficiency syndrome and cytomegalovirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcom

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Gross-structural defects in rats after acyclovir application on day 10 of gestation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

The Effect of Valaciclovir on Cytomegalovirus Viremia and Viruria Detected by Polymerase Chain Reaction in Patients with Advanced Human Immunodeficiency Virus Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

Comparative evaluation of eight commercial human cytomegalovirus IgG avidity assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2016.1173540

10.1586/14787210.2016.1173540

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference

PubMed ID

27043943